HPLC Analysis of Drug-to-Antibody Ratio (DAR) Using BioPro HIC BF

Introduction

Antibody-Drug Conjugates (ADCs) are a recent development of an important class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. ADCs are monoclonal antibodies chemically linked to biologically active small molecule drugs. By combining powerful cell-killing abilities of potent agents with target- specific antibodies, ADCs deliver cytotoxic drugs to the diseased cells, while limiting the toxicity in the non-targeted ones. A significant attribute of ADCs is the average number of drugs conjugated to the antibodies, the drug-to-antibody ratio (DAR). The DAR value affects the efficiency of the drug, as low drug loading reduces the potency, while high drug loading can negatively affect pharmacokinetics and toxicity.